Core Viewpoint - The company Jianbei Miaomiao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly the branded pharmaceutical segment's He Jigong and the traditional Chinese medicine segment's Baoji Wan [1] - The company attributed its success to focused brand management and effective market promotion execution [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]
港股异动 | 健倍苗苗(02161)涨超5% 中期纯利同比增长约20% 派息9.75港仙